CADTH has received notice of a pending submission from Amgen for Prolia (denosumab) for the treatment of men with osteoporosis.  For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website. Note that only patient groups may submit input.

For more details, go to: http://www.cadth.ca/en/products/cdr/patient-group-input/